BRPI0816268A2 - Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólida - Google Patents
Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólidaInfo
- Publication number
- BRPI0816268A2 BRPI0816268A2 BRPI0816268A BRPI0816268A BRPI0816268A2 BR PI0816268 A2 BRPI0816268 A2 BR PI0816268A2 BR PI0816268 A BRPI0816268 A BR PI0816268A BR PI0816268 A BRPI0816268 A BR PI0816268A BR PI0816268 A2 BRPI0816268 A2 BR PI0816268A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- controlled release
- oral dosage
- solid oral
- release solid
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000006186 oral dosage form Substances 0.000 title abstract 4
- 239000007787 solid Substances 0.000 title abstract 4
- 239000007909 solid dosage form Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 abstract 1
- 229960004099 azithromycin Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96750407P | 2007-09-05 | 2007-09-05 | |
| US12/002,417 US8124123B2 (en) | 2007-09-05 | 2007-12-17 | Controlled release azithromycin solid dosages forms |
| PCT/US2008/009169 WO2009032037A1 (en) | 2007-09-05 | 2008-07-30 | Controlled release azithromycin solid dosages forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0816268A2 true BRPI0816268A2 (pt) | 2017-08-22 |
Family
ID=40407900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0816268A BRPI0816268A2 (pt) | 2007-09-05 | 2008-07-30 | Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólida |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8124123B2 (OSRAM) |
| EP (2) | EP2197420A4 (OSRAM) |
| JP (2) | JP2010538062A (OSRAM) |
| KR (2) | KR20100063088A (OSRAM) |
| CN (2) | CN101861138A (OSRAM) |
| AR (1) | AR068368A1 (OSRAM) |
| AU (2) | AU2008295579A1 (OSRAM) |
| BR (1) | BRPI0816268A2 (OSRAM) |
| CA (2) | CA2697496A1 (OSRAM) |
| RU (2) | RU2010109358A (OSRAM) |
| WO (2) | WO2009032037A1 (OSRAM) |
| ZA (2) | ZA201001649B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE026034T2 (en) | 2002-12-13 | 2016-05-30 | Durect Corp | Oral delivery system containing an oral high-viscosity carrier |
| JP2011506318A (ja) | 2007-12-06 | 2011-03-03 | デュレクト コーポレーション | 経口医薬製剤 |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| TW201521769A (zh) | 2013-03-15 | 2015-06-16 | Durect Corp | 具有流變改質劑以減少溶解變異性之組成物 |
| US12274794B2 (en) | 2016-07-06 | 2025-04-15 | Orient Pharma Co., Ltd. | Oral dosage form with drug composition, barrier layer and drug layer |
| NZ752894A (en) * | 2016-10-06 | 2023-05-26 | Orbus Therapeutics Inc | Formulations for administration of eflornithine |
| CN109875970B (zh) * | 2019-01-08 | 2021-08-06 | 石家庄四药有限公司 | 阿奇霉素固体制剂及其制备方法 |
| CN113116859B (zh) * | 2021-04-12 | 2022-08-30 | 海南普利制药股份有限公司 | 阿奇霉素丸芯包衣制剂 |
| WO2023283427A2 (en) * | 2021-07-09 | 2023-01-12 | Verdure Biotech, Inc. | Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| EP0758244B2 (en) * | 1994-05-06 | 2008-02-13 | Pfizer Inc. | Controlled-release dosage forms of azithromycin |
| US5543417A (en) * | 1994-10-21 | 1996-08-06 | Merck & Co., Inc. | Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents |
| EP0951278A2 (en) * | 1997-01-03 | 1999-10-27 | ELAN CORPORATION, Plc | Sustained release cisapride mini-tablet formulation |
| US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| BRPI0414000B8 (pt) * | 2003-08-29 | 2021-05-25 | Lifecycle Pharma As | composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica |
| US20050239723A1 (en) * | 2004-04-27 | 2005-10-27 | Amin Avinash N | Compositions and methods useful for treatment of acne |
| JP2008524317A (ja) | 2004-12-21 | 2008-07-10 | ファイザー・プロダクツ・インク | 腸溶コーティングされたアジスロマイシン多粒子 |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| WO2006135480A2 (en) * | 2005-04-08 | 2006-12-21 | Abbott Laboratories | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts |
| CN101304750A (zh) * | 2005-11-09 | 2008-11-12 | 陶氏制药科学公司 | 用于治疗肉芽肿性酒糟鼻的阿奇霉素 |
| US7704959B2 (en) * | 2006-10-03 | 2010-04-27 | Dow Pharmaceutical Sciences | Azithromycin for the treatment of nodular acne |
-
2007
- 2007-12-17 US US12/002,417 patent/US8124123B2/en not_active Expired - Fee Related
-
2008
- 2008-07-30 CA CA2697496A patent/CA2697496A1/en not_active Abandoned
- 2008-07-30 AU AU2008295579A patent/AU2008295579A1/en not_active Abandoned
- 2008-07-30 BR BRPI0816268A patent/BRPI0816268A2/pt not_active IP Right Cessation
- 2008-07-30 KR KR1020107006490A patent/KR20100063088A/ko not_active Withdrawn
- 2008-07-30 CN CN200880105792A patent/CN101861138A/zh active Pending
- 2008-07-30 JP JP2010523991A patent/JP2010538062A/ja not_active Revoked
- 2008-07-30 WO PCT/US2008/009169 patent/WO2009032037A1/en not_active Ceased
- 2008-07-30 EP EP08780336A patent/EP2197420A4/en not_active Withdrawn
- 2008-07-30 RU RU2010109358/15A patent/RU2010109358A/ru unknown
- 2008-09-04 AR ARP080103847A patent/AR068368A1/es not_active Application Discontinuation
- 2008-09-04 EP EP08829925A patent/EP2197453A4/en not_active Withdrawn
- 2008-09-04 CA CA2697537A patent/CA2697537A1/en not_active Abandoned
- 2008-09-04 CN CN200880105803A patent/CN101835475A/zh active Pending
- 2008-09-04 JP JP2010524023A patent/JP2010538066A/ja not_active Withdrawn
- 2008-09-04 WO PCT/US2008/010355 patent/WO2009032268A1/en not_active Ceased
- 2008-09-04 KR KR1020107006491A patent/KR20100054842A/ko not_active Withdrawn
- 2008-09-04 RU RU2010109359/15A patent/RU2010109359A/ru not_active Application Discontinuation
- 2008-09-04 AU AU2008296903A patent/AU2008296903A1/en not_active Abandoned
-
2010
- 2010-03-08 ZA ZA2010/01649A patent/ZA201001649B/en unknown
- 2010-03-10 ZA ZA2010/01705A patent/ZA201001705B/en unknown
-
2012
- 2012-01-25 US US13/357,722 patent/US20120121702A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008296903A1 (en) | 2009-03-12 |
| KR20100054842A (ko) | 2010-05-25 |
| AR068368A1 (es) | 2009-11-11 |
| ZA201001649B (en) | 2010-11-24 |
| US20120121702A1 (en) | 2012-05-17 |
| JP2010538062A (ja) | 2010-12-09 |
| EP2197420A1 (en) | 2010-06-23 |
| CN101835475A (zh) | 2010-09-15 |
| EP2197453A4 (en) | 2010-10-20 |
| US8124123B2 (en) | 2012-02-28 |
| RU2010109359A (ru) | 2011-10-20 |
| RU2010109358A (ru) | 2011-10-20 |
| CN101861138A (zh) | 2010-10-13 |
| WO2009032037A1 (en) | 2009-03-12 |
| CA2697496A1 (en) | 2009-03-12 |
| ZA201001705B (en) | 2010-12-29 |
| KR20100063088A (ko) | 2010-06-10 |
| EP2197453A1 (en) | 2010-06-23 |
| US20090060994A1 (en) | 2009-03-05 |
| WO2009032268A1 (en) | 2009-03-12 |
| CA2697537A1 (en) | 2009-03-12 |
| JP2010538066A (ja) | 2010-12-09 |
| EP2197420A4 (en) | 2010-10-20 |
| AU2008295579A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0816268A2 (pt) | Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólida | |
| DK2077729T3 (da) | Orale probiotiske doseringsformer | |
| BR112014014025A2 (pt) | prótese luminal e dispostivo de implante gastrointestinal | |
| GB0720297D0 (en) | Web server administration | |
| ZA200904436B (en) | Modified release ibuprofen solid oral dosage form | |
| BRPI0814299A2 (pt) | Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida | |
| PL2457562T3 (pl) | Stałe postacie dawkowania leku o zmodyfikowanym uwalnianiu o kinetyce rzędu zerowego | |
| BR112012000968A2 (pt) | composto, composição e método para inibir uma fosfatidil inositol-3 cinase. | |
| BRPI0909085A2 (pt) | estrutura absorvente de oxigênio de múltiplas camadas, métodos para produzir uma estrutura absorvente de oxigênio de múltiplas camadas, e, embalagem. | |
| EP2242484A4 (en) | EXTENDED RELEASE DOSAGE FORM FOR LUBRICATING ORAL CAVITY | |
| IL212008A0 (en) | Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules | |
| IL251175A0 (en) | Stabilized dosage of picoplatin | |
| BRPI1016132A2 (pt) | composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável. | |
| FR2945947B1 (fr) | Compositions pharmaceutiques flottantes a liberation controlee | |
| BRPI0810727A2 (pt) | Dispositivo para a aplicação oral de uma substância. | |
| BRPI0908114A2 (pt) | tabuleta oral de liberação controlada | |
| BRPI0719502A2 (pt) | Película, artigo, pacote e método para formar uma película multicamada | |
| ZA201100615B (en) | Appetising medicament for oral administration in solid form | |
| BRPI0719880A2 (pt) | Forma de dosagem sólida farmacêutica para administração oral e método para preparar a mesma. | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| EP2226071A4 (en) | COMPOSITIONS FOR ORAL ADMINISTRATION | |
| GB0710439D0 (en) | Oral dosage form | |
| IL210393A0 (en) | Administration regime for nitrocatechols | |
| EP2138168A4 (en) | ORAL ADMINISTRATION AGENT AND METHOD FOR PRODUCING THE SAME | |
| BRPI0718565A2 (pt) | Forma de dosagem sólida, e, método de produção de uma forma de dosagem sólida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |